Lung function before and after pediatric allogeneic hematopoietic stem cell transplantation: A predictive role for DLCOa/VA

Troy C. Quigg, Young Jee Kim, W. Scott Goebel, Paul R. Haut

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND:: Pre-allogeneic hematopoietic stem cell transplantation (aHSCT) and post-aHSCT lung function of 41 eligible patients at Riley Hospital for Children were assessed to identify risk factors for post-aHSCT morbidity and mortality. OBSERVATIONS:: One year post-aHSCT pulmonary function tests were significantly lower compared with baseline. These findings recovered at 2 years post-aHSCT. Refractory disease before aHSCT correlated with lower pulmonary function tests after aHSCT. Graft-versus-host disease was significantly associated with higher post-aHSCT residual volume. Importantly, low pre-aHSCT carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume was predictive of death. CONCLUSIONS:: Among survivors, lung function improves over time after pediatric aHSCT. Measurement of carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume before pediatric aHSCT should be further investigated as a predictor of pulmonary dysfunction and mortality.

Original languageEnglish (US)
Pages (from-to)304-309
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume34
Issue number4
DOIs
StatePublished - May 1 2012

Fingerprint

Hematopoietic Stem Cell Transplantation
Pediatrics
Lung
Respiratory Function Tests
Carbon Monoxide
Hemoglobins
Residual Volume
Mortality
Graft vs Host Disease
Survivors
Morbidity

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • DLCOa/VA
  • Graft-versus-host disease
  • Mortality
  • Pulmonary function tests

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

@article{b0065d82385c4aa5a612e80ef65d9de9,
title = "Lung function before and after pediatric allogeneic hematopoietic stem cell transplantation: A predictive role for DLCOa/VA",
abstract = "BACKGROUND:: Pre-allogeneic hematopoietic stem cell transplantation (aHSCT) and post-aHSCT lung function of 41 eligible patients at Riley Hospital for Children were assessed to identify risk factors for post-aHSCT morbidity and mortality. OBSERVATIONS:: One year post-aHSCT pulmonary function tests were significantly lower compared with baseline. These findings recovered at 2 years post-aHSCT. Refractory disease before aHSCT correlated with lower pulmonary function tests after aHSCT. Graft-versus-host disease was significantly associated with higher post-aHSCT residual volume. Importantly, low pre-aHSCT carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume was predictive of death. CONCLUSIONS:: Among survivors, lung function improves over time after pediatric aHSCT. Measurement of carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume before pediatric aHSCT should be further investigated as a predictor of pulmonary dysfunction and mortality.",
keywords = "Allogeneic hematopoietic stem cell transplantation, DLCOa/VA, Graft-versus-host disease, Mortality, Pulmonary function tests",
author = "Quigg, {Troy C.} and Kim, {Young Jee} and Goebel, {W. Scott} and Haut, {Paul R.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1097/MPH.0b013e3182346ed8",
language = "English (US)",
volume = "34",
pages = "304--309",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Lung function before and after pediatric allogeneic hematopoietic stem cell transplantation

T2 - A predictive role for DLCOa/VA

AU - Quigg, Troy C.

AU - Kim, Young Jee

AU - Goebel, W. Scott

AU - Haut, Paul R.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - BACKGROUND:: Pre-allogeneic hematopoietic stem cell transplantation (aHSCT) and post-aHSCT lung function of 41 eligible patients at Riley Hospital for Children were assessed to identify risk factors for post-aHSCT morbidity and mortality. OBSERVATIONS:: One year post-aHSCT pulmonary function tests were significantly lower compared with baseline. These findings recovered at 2 years post-aHSCT. Refractory disease before aHSCT correlated with lower pulmonary function tests after aHSCT. Graft-versus-host disease was significantly associated with higher post-aHSCT residual volume. Importantly, low pre-aHSCT carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume was predictive of death. CONCLUSIONS:: Among survivors, lung function improves over time after pediatric aHSCT. Measurement of carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume before pediatric aHSCT should be further investigated as a predictor of pulmonary dysfunction and mortality.

AB - BACKGROUND:: Pre-allogeneic hematopoietic stem cell transplantation (aHSCT) and post-aHSCT lung function of 41 eligible patients at Riley Hospital for Children were assessed to identify risk factors for post-aHSCT morbidity and mortality. OBSERVATIONS:: One year post-aHSCT pulmonary function tests were significantly lower compared with baseline. These findings recovered at 2 years post-aHSCT. Refractory disease before aHSCT correlated with lower pulmonary function tests after aHSCT. Graft-versus-host disease was significantly associated with higher post-aHSCT residual volume. Importantly, low pre-aHSCT carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume was predictive of death. CONCLUSIONS:: Among survivors, lung function improves over time after pediatric aHSCT. Measurement of carbon monoxide diffusing capacity adjusted for hemoglobin and alveolar volume before pediatric aHSCT should be further investigated as a predictor of pulmonary dysfunction and mortality.

KW - Allogeneic hematopoietic stem cell transplantation

KW - DLCOa/VA

KW - Graft-versus-host disease

KW - Mortality

KW - Pulmonary function tests

UR - http://www.scopus.com/inward/record.url?scp=84862812786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862812786&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e3182346ed8

DO - 10.1097/MPH.0b013e3182346ed8

M3 - Article

C2 - 22246156

AN - SCOPUS:84862812786

VL - 34

SP - 304

EP - 309

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 4

ER -